The New England journal of medicine
The most recent articles from:
N. Engl. J. Med.
2022
-
Editorial Comment
VITAL Findings - A Decisive Verdict on Vitamin D Supplementation.
-
Randomized Controlled Trial
Tirzepatide Once Weekly for the Treatment of Obesity.
Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. ⋯ In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).